Home
Live Updates
Data from Newrons study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS) -April 08, 2024 at 07:06 am EDT : comparemela.com
Data from Newron's study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS) -April 08, 2024 at 07:06 am EDT
Data from study 014/015, a phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia for up to one year
Presentation of study design for potentially...
Related Keywords
United Kingdom ,
Seika ,
Kyongsang Bukto ,
South Korea ,
India ,
Sri Lanka ,
Switzerland ,
Japan ,
United Arab Emirates ,
Milan ,
Lombardia ,
Italy ,
Bresso ,
Israel ,
United States ,
Canada ,
Australia ,
America ,
Swiss ,
,
Dusseldorf Stock Exchange ,
Newron Pharmaceuticals ,
Supernus Pharmaceuticals ,
Schizophrenia International Research Society ,
Swiss Exchange ,
European Union ,
Negative Syndrome Scale ,
Clinical Global Impression ,
Strauss Carpenter Level ,
Latin America ,
Meiji Seika ,
comparemela.com © 2020. All Rights Reserved.